1-18 of 18
Sherene Loi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal L. Jhaveri, Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Tomas G. Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García-Estévez, Elena López-Miranda, J. Alejandro Pérez-Fidalgo, Jose M. Pérez-García, Jiajie Yu, Jill Fredrickson, Heather M. Moore, Ching-Wei Chang, John W. Bond, Jennifer Eng-Wong, Mary R. Gates, Elgene Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 754–766.
https://doi.org/10.1158/1078-0432.CCR-23-1796
Published: 16 February 2024
View article titled, Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Open the PDF for Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Andrea Joaquin Garcia, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, István Laáng, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M. Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4908–4919.
https://doi.org/10.1158/1078-0432.CCR-23-1267
Published: 01 December 2023
View article titled, Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Open the PDF for Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00 in another window
Includes: Supplementary data
Journal Articles

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3691–3705.
https://doi.org/10.1158/1078-0432.CCR-23-0370
Published: 15 September 2023
View article titled, Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Open the PDF for Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet

Roberto Salgado, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2728–2729.
https://doi.org/10.1158/1078-0432.CCR-22-0783
Published: 01 July 2022
View article titled, What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet
Open the PDF for What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet in another window
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Margaret L. Axelrod, Mellissa J. Nixon, Paula I. Gonzalez-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell, Violeta Sanchez, Susan R. Opalenik, Sherene Loi, Jing Zhou, Sean Mackay, Brent N. Rexer, Vandana G. Abramson, Valerie M. Jansen, Simon Mallal, Joshua Donaldson, Sara M. Tolaney, Ian E. Krop, Ana C. Garrido-Castro, Jonathan D. Marotti, Kevin Shee, Todd W. Miller, Melinda E. Sanders, Ingrid A. Mayer, Roberto Salgado, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5668–5681.
https://doi.org/10.1158/1078-0432.CCR-19-3685
Published: 02 November 2020
View article titled, Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Open the PDF for Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Metastatic Breast Cancer: TIL it is Too Late

Peter Savas, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 526–528.
https://doi.org/10.1158/1078-0432.CCR-19-3490
Published: 03 February 2020
View article titled, Metastatic Breast Cancer: TIL it is Too Late
Open the PDF for Metastatic Breast Cancer: TIL it is Too Late in another window
Journal Articles

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim, Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, José Perez-Garcia, Philippe Aftimos, Philippe L. Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas C. Turner, Fabrice Andre, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 354–363.
https://doi.org/10.1158/1078-0432.CCR-19-1164
Published: 15 January 2020
View article titled, Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Open the PDF for Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study in another window
Includes: Supplementary data
Journal Articles

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G. House, Peter Savas, Junyun Lai, Amanda X.Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (2): 487–504.
https://doi.org/10.1158/1078-0432.CCR-19-1868
Published: 15 January 2020
View article titled, Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Open the PDF for Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Hope S. Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina A. Piha-Paul, Philippe L. Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-17-3452
Published: 14 June 2018
View article titled, Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Open the PDF for Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

Fabrice Andre, Maria V. Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 28–33.
https://doi.org/10.1158/1078-0432.CCR-11-2701
Published: 02 January 2013
View article titled, Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
Open the PDF for Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer in another window
Journal Articles

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

Hatem A. Azim, Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiriou, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1341–1351.
https://doi.org/10.1158/1078-0432.CCR-11-2599
Published: 01 March 2012
View article titled, Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Open the PDF for Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling in another window
Includes: Supplementary data
Journal Articles

Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment

Christine Desmedt, Samira Majjaj, Naima Kheddoumi, Sandeep K. Singhal, Benjamin Haibe-Kains, Frank El Ouriaghli, Carole Chaboteaux, Stefan Michiels, Françoise Lallemand, Fabrice Journe, Hughes Duvillier, Sherene Loi, John Quackenbush, Sophie Dekoninck, Cédric Blanpain, Laurence Lagneaux, Nawal Houhou, Mauro Delorenzi, Denis Larsimont, Martine Piccart, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1004–1014.
https://doi.org/10.1158/1078-0432.CCR-11-0383
Published: 14 February 2012
View article titled, Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment
Open the PDF for Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment in another window
Includes: Supplementary data
Journal Articles

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

Christine Desmedt, Fanny Piette, Sherene Loi, Yixin Wang, Françoise Lallemand, Benjamin Haibe-Kains, Giuseppe Viale, Mauro Delorenzi, Yi Zhang, Mahasti Saghatchian d'Assignies, Jonas Bergh, Rosette Lidereau, Paul Ellis, Adrian L. Harris, Jan G.M. Klijn, John A. Foekens, Fatima Cardoso, Martine J. Piccart, Marc Buyse, Christos Sotiriou, on behalf of the TRANSBIG Consortium
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3207–3214.
https://doi.org/10.1158/1078-0432.CCR-06-2765
Published: 01 June 2007
View article titled, Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
Open the PDF for Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series in another window